JAZZ FY2025 SEC EDGAR DEF 14A #58 of 168 in industry

Jazz Pharmaceuticals plc CEO pay ratio

The CEO earned $19.4M in FY2025 against median worker pay of $281,424 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
L2
Filing date
2026-06-08
Industry
Chemicals & Pharmaceuticals
Industry rank
#58/168

Data updated August 2026

Subscribe to Jazz Pharmaceuticals plc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
69:1
Moderate (Scale: 0–1000:1)
CEO pay
$19.4M
Median worker
$281,424

Answer first

Jazz Pharmaceuticals plc's FY2025 CEO total of $19.4M ranks #176 of 1,423 complete filings; its 69:1 pay ratio ranks #828. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $281,424. Industry placement uses the FY2025 SIC-28 peer cohort (# 58 of 168, 66th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#176
$19.4M of 1,423 FY2025
Ratio rank
#828
69:1 of 1,423
Industry pct
66th
above the industry median pay ratio

How Jazz Pharmaceuticals plc ranks nationally

Jazz Pharmaceuticals plc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$19,418,256 Top 12% higher than 88% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). Below this entry. $17,500,000–$20,000,000: 54 companies (4%). This entry sits in this band. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Jazz Pharmaceuticals plc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($19.4M) against pay ratio (69:1) for Jazz Pharmaceuticals plc (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both7015949.311875670.916735392.521595114.126454835.840.5:148.5:156.5:164.5:172.5:1CEO total payPay ratio (CEO : median worker)Jazz Pharmaceuticals plc, CEO total pay: 19418256 · Pay ratio (CEO : median worker): 69:1Jazz Pharmaceuticals plcTg Therapeutics, Inc., CEO total pay: 25571250 · Pay ratio (CEO : median worker): 67:1Tg Therapeutics, Inc.Niagen Bioscience, Inc., CEO total pay: 8381900 · Pay ratio (CEO : median worker): 67:1Niagen Bioscience, Inc.Chemours Co, CEO total pay: 8600301 · Pay ratio (CEO : median worker): 71:1Chemours CoEcovyst Inc., CEO total pay: 10023845 · Pay ratio (CEO : median worker): 65:1Ecovyst Inc.
Jazz Pharmaceuticals plc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Jazz Pharmaceuticals plc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Jazz Pharmaceuticals plc

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
69:1
FY2025
vs prior FY
+14:1
from FY2024 55:1
CEO $ YoY
+25%
$19.4M latest
Filings shown
5
FY2021–2025
Jazz Pharmaceuticals plc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $15.7M - $212,134 74:1 -
2022 $17.3M +10% $236,307 73:1 -1:1
2023 $15.3M -11% $234,605 65:1 -8:1
2024 $15.5M +1.2% $281,421 55:1 -10:1
2025 $19.4M +25% $281,424 69:1 +14:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1232524, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
69:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$19.4M
Companies in Industry
168
vs. Industry Median
Above
#58 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Jazz Pharmaceuticals plc: MODEST · PEAK pay ratio

Jazz Pharmaceuticals plc's FY2025 CEO total $19.4M ranks #176 of 1,423 complete filings (higher third by dollars). the CEO earned 69× the median employee ($281,424) in FY2025.

Median employee $281,424 (ELITE-MED); MODEST · PEAK stamps put about 69 median-wage years per CEO year.

CEO Total Pay

$19.4M

FY2025 Summary Compensation, well above median

Pay Ratio

69:1

Near industry median

Jazz Pharmaceuticals plc in the higher-dollar third

Jazz Pharmaceuticals plc's FY2025 CEO total $19.4M ranks #176 of 1,423 complete filings (higher third by dollars). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Jazz Pharmaceuticals plc's $19.4M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #176 and ratio rank #828 split - treat 69:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$19.4M
Median Employee Pay
$281,424
Pay Ratio
69:1
Filing Date
2026-06-08

Company Info

Ticker
JAZZ
CIK
1232524
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
L2
View SEC filings →
SEC EDGAR DEF 14A for CIK 1232524, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Jazz Pharmaceuticals plc's FY2025 CEO total $19.4M ranks #176 of 1,423 complete filings (higher third by dollars).

Read with Jazz Pharmaceuticals plc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · PEAK · ELITE-MED.

Smithfield Foods Inc · PEAK

ABS(ceo_total_comp) peer at $19.3M (Δ $81K lighter vs Jazz Pharmaceuticals plc); HIGH · PAR-MED vs this page's MODEST · PEAK · ELITE-MED.
State Street Corp · PEAK

ABS(ceo_total_comp) peer at $19.5M (Δ $109K heavier vs Jazz Pharmaceuticals plc); HIGH · PAR-MED vs this page's MODEST · PEAK · ELITE-MED.
Monster Beverage Corp · PEAK

ABS(ceo_total_comp) peer at $19.3M (Δ $121K lighter vs Jazz Pharmaceuticals plc); STEEP · HIGH-MED vs this page's MODEST · PEAK · ELITE-MED.
Novagold Resources Inc · PEAK

ABS(ceo_total_comp) peer at $19.3M (Δ $166K lighter vs Jazz Pharmaceuticals plc); MODEST · ELITE-MED vs this page's MODEST · PEAK · ELITE-MED.
ImmunityBio, Inc. (SIC 28 pole)

ImmunityBio, Inc. stamps MODEST · UNFILED nearest in-SIC by ABS(pay_ratio) to Jazz Pharmaceuticals plc's MODEST filing.
National dual ranks · #176/#828

Jazz Pharmaceuticals plc's FY2025 package sits #176 by CEO dollars and #828 by ratio under PEAK · MODEST.
Ratio primer · MODEST

Jazz Pharmaceuticals plc's MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Jazz Pharmaceuticals plc (CIK 1232524), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.